Spyre Therapeutics
spyre.com
Actively hiring
Immunology & Inflammation Therapeutics
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
11-50
employees, estimated range
Hiring now
1
+1 posted in 30 days
Backers
2
RA Capital Management, Aisling Capital
Momentum
28/100
hiring for its size, in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management 
Aisling Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
AltruBio. Developing safer, more durable treatments to improve the lives of patients.
We are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases.
Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions.
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
SFA Therapeutics is developing a next-generation oral immune tolerance therapy for psoriasis. Our investigational approach is designed to…
News
Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
Spyre Therapeutics (NasdaqGS:SYRE) completed a public stock offering raising about US$350 million to fund its drug pipeline. The equity raise is aimed at advancing clinical programs in gastroenterology, rheumatology, and dermatology indications. Managemen
Read more
Report
Spyre Therapeutics Announces Major Equity Financing Agreement
Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.
Read more
Report
Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
Read more
Report
Report
Spyre Therapeutics Shares Fall 13 Percent to $81 After Pricing a $350 Million Stock Offering at $85 a Share
Spyre Therapeutics shares fell 13% after the biotech priced a $350 million stock sale at an 8.3% discount, funding trials while diluting existing shareholders.
Read more
Report
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - October 5, 2026
Read more
Report
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (
Read more
Report
Spyre Therapeutics stock falls on public offering launch
Investing.com -- Spyre Therapeutics Inc (NASDAQ:SYRE) shares fell 2.9% in after-hours trading Monday following the company
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Spyre Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
1
Stack modernity
53/100
Cloud & platforms
GCP
Developer tools
Microsoft Excel
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$200k
Typical range
$200k
Open positions
1
1
Jobs
Architect
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Architect | 1 | $200k | $200k |
Highest paying role
Associate Director, Clinical Supply Chain
$200k
Normalized to USD per year
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Operations
100% ▲